Posted by psychobot5000 on February 2, 2007, at 16:49:22
In reply to Vanoxerine and other DA reuptake inhibitors, posted by halcyondaze on February 2, 2007, at 14:49:55
I agree that tranylcypromine has too many inconvenient side-effects and dangers to become a widespread drug of abuse--so it's more or less a non-issue.
As for the rest...I think a large part of the reason that amphetamines and methylphenidate are used widely, and all the rest are not is that those two are grandfathered into the system. To put it another way, after seven decades of medical amphetamine use and rigorous testing, its a well-known substance...and unfortunately for anti-drug crusaders, it has demonstrated a clear place in medicine.
Phenmetrazine, I think is probably more euphoric and abusable (?), and was developed later. It never managed to earn its place before concerns about abusability shut it down. As for Amineptine, well, it didn't have decades and decades of use and testing to support it when it was shut down--during the decades of its use a substantial wariness had -already developed- toward anything dopaminergic--and it does cause liver damage occasionally (though it seems a substantially less severe problem than with, say, nefazodone).
It's too bad. In my view, political concerns are suppressing the development of legitimate medical treatments. But it seems that the bodies that make these decisions feel strongly about even -potential- drugs of abuse, possibly because it causes negative publicity for psychopharmacology in general.
As for vanoxerine, it diminishes DA release, like bupropion, so it doesn't sound abusable. I think that's why it's being developed. I'm not convinced it will be very useful.
poster:psychobot5000
thread:729102
URL: http://www.dr-bob.org/babble/20070201/msgs/729135.html